The purpose of this study is to conduct a multi-country, multi-site, epidemiologic study designed to assess the proportion of interferon gamma release assay (IGRA) positivity, at site level, and to build capacity to conduct a future TB vaccine efficacy study.
Study Type
OBSERVATIONAL
Enrollment
7,203
IGRA status per site
Proportion of participants with a positive IGRA, per site, calculated using per protocol population. 95% CI will summarize the precision associated with the estimate.
Time frame: Screening
IGRA status by age group per site
Proportion of participants with a positive IGRA, by age group (15 to 24 \[inclusive\], and 25 to 34 years of age \[inclusive\]) per site, calculated using per protocol population. 95% CI to summarize the precision associated with the estimates.
Time frame: Screening
Suspected pulmonary TB during follow-up period
Incidence rate of participants with suspected TB to be summarized by country. Exact 95% CI to be provided
Time frame: Day 1 up to 30 months
Laboratory-confirmed pulmonary TB during follow-up period
Incidence rate of participants with suspected TB to be summarized by country. Exact 95% CI to be provided.
Time frame: Day 1 up to 30 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Investigational Site
Dhaka, Bangladesh
Investigational Site
Porto Alegre, Brazil
Investigational Site
Rio de Janeiro, Brazil
Investigational Site
Kinshasa, Democratic Republic of the Congo
Investigational Site
Pune, India
Investigational Site
Bandung, West Java, Indonesia
Investigational Site
Bakti, Indonesia
Investigational Site
Persabahan, Indonesia
Investigational Site
Kisumu, Kenya
Investigational Site
Mombasa, Kenya
...and 26 more locations